IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

By sjmartinez • September 28, 2023

Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, Ikeda M, Tsuchiya K, Aoki KI, Jia J, Lencioni R. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. PMID: 37767068; PMCID: PMC10521324.

Tags: Atezolizumab, Barcelona Clinic Liver Cancer stage B, Bevacizumab, Hematology/Oncology, Publications, unresectable

Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia[...]

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira[...]

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis

Britten K, Lipsyc-Sharf M, Yang EH, McCloskey S, Sedrak MS, Teshome M, LaBarbera J, Bardia A, McAndrew N. Socioeconomic disparities in long-term heart failure risk[...]